This page shows what was measured, who it was measured in, and what that does not settle.
What Rifampicin does in the body
In the treatment of both tuberculosis and the meningococcal carrier state, the small number of resistant cells present within large populations of susceptible cells can rapidly become the predominant type.
From the FDA-approved label: Rifampin inhibits DNA-dependent RNA polymerase activity in susceptible Mycobacterium tuberculosis organisms. Specifically, it interacts with bacterial RNA polymerase but does not inhibit the mammalian enzyme.
Why people take it. In the treatment of both tuberculosis and the meningococcal carrier state, the small number of resistant cells present within large populations of susceptible cells can rapidly become the predominant type.
What happened in people
RNAWiki has not yet published a reviewed conclusion for this use.
§ A fixed RNAWiki sentence
Where this came from
Wording RNAWiki always uses, not a finding about this substance.
No reviewed claim names a result for any goal on this record.
No source is stored against this line.
The limit that matters most
Not recorded.
Where it acts
Not recorded.
Kind of result
No result is published, so no kind of result applies yet
Supervision
Professional supervision is normally required. A regulator classifies this substance in a way that restricts how it is supplied.
What the registries record it as
The substance registry classes this as chemical.
FDA substance registry · VJT6J7R4TR · read 2026-08-29
Its recorded molecular formula is C43H58N4O12, weighing 822.95.
US prescribing information · cb59a48c-f66b-4ea0-809c-de0e4be2f8c2 · read 2026-08-30
Where each sentence above came from
The use the label states, quoted from it. No plain-language version of this sentence has been written.
The use the label states, quoted from it. It is written for a clinician, not for a reader without medical training.
No statement of the main limit is recorded.
The four opening statements run to 100 words.
Words this page uses
Four words worth knowing first
Chosen from what this page shows, with each one explained before the word it depends on.
Biomarker
A biomarker is a number from a test that stands in for something about health.
A picture of it, and where the picture fails
A biomarker is like a fuel gauge.
Where that stops being true. A gauge is wired to the tank. Many biomarkers are only loosely tied to health.
What people get wrong. A better number is read as a better life. Several medicines improved a number and helped nobody.
A measurable indicator used as a substitute for a clinical outcome of interest.
Placebo
A placebo is a dummy treatment given so the real one can be compared with it.
A picture of it, and where the picture fails
A placebo is like a blank control in an experiment.
Where that stops being true. A blank does nothing. People given a placebo often do get better.
What people get wrong. A placebo effect is read as imaginary. The improvement is measured and real.
An inactive intervention matched in appearance to the test intervention, used to control for non-specific effects.
Comparator
A comparator is whatever the treatment was measured against.
A picture of it, and where the picture fails
It is like the other runner in a race.
Where that stops being true. A race has one winner. A study can show both arms improved.
What people get wrong. Results are read without asking what the other group got. Beating nothing is not beating a treatment.
The control condition against which the experimental intervention is assessed.
What happened in people◇Read from sources, not yet reviewed
What happened in people
Each card is one study: the exact question it asked, who was in it, and whether it showed what it set out to show.
Compare Effectiveness in Curbing Transmission of Leprosy of Three Different Approaches of Post Exposure Prophylaxis
✗ The study did not show it
Who was studied
NCT03662022
How many people
144000
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Oral
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
To evaluate effectiveness of PEP based on a combination of rifampicin and bedaquiline (BE-PEP), in preventing leprosy among contacts of incident cases.
✗ The study did not show it
Who was studied
NCT05597280
How many people
124000
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Oral
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
the total number of TB cases detected / 100 000 inhabitants
✗ The study did not show it
Who was studied
NCT05406453
How many people
98362
Study design
Not applicable
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Oral
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
Primary Endpoint: Diagnostic accuracy (sensitivity, specificity, PPV, NPV) of NPOC assays (tongue swab and sputum swab) compared against the microbiological reference standard (MRS: sputum culture).
✗ The study did not show it
Who was studied
NCT07420881
How many people
60000
Study design
Not applicable
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Oral
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
Primary Objective 1: To evaluate the diagnostic yield and comparative accuracy of diagnostic algorithms initiated by CAD CXR-AI and/or NPOC tongue swab and sputum swab screening as initial screening tools in a facility-based case finding strategy
✗ The study did not show it
Who was studied
NCT07517471
How many people
37000
Study design
Not applicable
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Oral
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
Sensitivity
✗ The study did not show it
Who was studied
NCT04923958
How many people
26436
Study design
Not applicable
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Oral
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
What we know
RNAWiki holds 6 written-up human studies for this substance, each with the question it asked.
How we know it
Each card names the study, the number of people and what the study set out to measure.
What this does not prove
These summaries were written by a person and have not been signed off as reviewed claims.
Why it matters
A study that failed is as informative as one that worked, and both are here.
What we still do not know
No reviewed claim exists, so no exact population, effect size or interval is published yet.
What is missing or unclear◇Read from sources, not yet reviewed
Were people like you studied?
RNAWiki cannot tell whether a study fits you. It can show who was in it, and where the result stops carrying.
Who was studied
People similar to this profile were included.
In the treatment of both tuberculosis and the meningococcal carrier state, the small number of resistant cells present within large populations of susceptible cells can rapidly become the predominant type.
Who is missing from the studies
Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.
What the label states about particular groups
On older people, the label states: “Clinical studies of rifampin did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects.”
US prescribing information · cb59a48c-f66b-4ea0-809c-de0e4be2f8c2 · read 2026-08-30
On people who are pregnant, the label states: “–Teratogenic Effects Rifampin has been shown to be teratogenic in rodents.”
US prescribing information · cb59a48c-f66b-4ea0-809c-de0e4be2f8c2 · read 2026-08-30
On people who are breastfeeding, the label states: “Because of the potential for tumorigenicity shown for rifampin in animal studies, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.”
US prescribing information · cb59a48c-f66b-4ea0-809c-de0e4be2f8c2 · read 2026-08-30
Where the result stopped carrying
This is a scope explorer, not a diagnosis engine.
It shows who was studied so you can see whether people similar to you were included.
RNAWiki cannot tell whether a study fits you. It can show who was in it.
What it would be like to take◇Read from sources, not yet reviewed
Why it might seem to do nothing
A real effect and a noticed effect are different things. These are the recorded reasons the two come apart.
It was studied in different people
The people in the studies were not much like the reader.
On this record: Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.
The evidence may simply be wrong
Small early studies often do not hold up.
On this record: RNAWiki has not yet published a reviewed conclusion for this use.
Other reasons RNAWiki checked and found nothing for (11)
It was studied for a different goal
The studies measured something else entirely. Nothing in this record points to this reason.
A different form was studied
The studied form is not the form on the shelf. Nothing in this record points to this reason.
There was nothing to correct
Where a level is already normal, topping it up may change nothing. Nothing in this record points to this reason.
Something else had to happen too
In the studies it was paired with training, a diet or another treatment. Nothing in this record points to this reason.
The change is too small to feel
A real change can still sit below what a person notices. Nothing in this record points to this reason.
Day-to-day swing hides it
Sleep, food, stress and time of day move most numbers more than this would. Nothing in this record points to this reason.
Not enough time yet
The studies ran longer than the person has waited. Nothing in this record points to this reason.
It was not taken as studied
Missed days change the result, and studies count them. Nothing in this record points to this reason.
Something else changed at the same time
Two changes at once cannot be told apart afterwards. Nothing in this record points to this reason.
The product may not be what it says
Contents of a sold product are not always what the label states. Nothing in this record points to this reason.
No recorded reason
RNAWiki has nothing stored that would explain it. Nothing in this record points to this reason.
None of these is a reason to take more. Taking more is not a step this page ever suggests.
What it would be like to take◇Read from sources, not yet reviewed
What taking it involves
The recorded facts about getting hold of it and using it. Nothing here is a suggestion about what you should do.
How it is supplied
Prescription only
❝ Quoted from a source
Where this came from
Copied from a source RNAWiki stored, with the source named.
Read from the recorded approval status.
No source is stored against this line.
Form and route
Oral
✎ Source-linked record
Where this came from
A person wrote this into the record with the study named beside it. No reviewer has signed it off.
The form and route recorded on this substance.
No source is stored against this line.
Who oversees it
Professional supervision is normally required. A regulator classifies this substance in a way that restricts how it is supplied.
❝ Quoted from a source
Where this came from
Copied from a source RNAWiki stored, with the source named.
Suppression classes recorded: S4.
No source is stored against this line.
What is in the pack
Sold as capsule, injectable, tablet, injection, powder, lyophilized, for solution, given by the oral, injection, intravenous route.
✎ Source-linked record
Where this came from
A person wrote this into the record with the study named beside it. No reviewer has signed it off.
Recorded notes on how this is sold and what that means for what is in the pack.
No source is stored against this line.
Where it is registered
Regulatory records are listed in the technical disclosure at the foot of this page.
# Counted from records
Where this came from
A count of rows RNAWiki holds. It describes our records, not your body.
Register entries are stored per jurisdiction and shown with their dates.
No source is stored against this line.
Why people stop
Not recorded.
∅ Nothing recorded
Where this came from
RNAWiki holds nothing here and says so rather than guessing.
No record of why people stopped taking it is stored for this substance.
No source is stored against this line.
What it would be like to take∅Nothing found in the sources checked
What can go wrong
Sorted by where each line came from. A regulator's label and a report somebody sent in are not the same kind of fact.
∅Nothing found in the sources checked
No harm is recorded against this substance in the sources RNAWiki checked. Finding nothing is not the same as showing there is nothing.
The sources listed were searched and held nothing. That is not the same as nothing existing.
Over a long time. No completed tested study window is recorded, so long-term effects are not established by the registry record.
Groups the studies covered thinly. Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.
What is missing or unclear◇Read from sources, not yet reviewed
Does the exact form matter?
Evidence belongs to the exact thing that was tested. A different salt, a different mixture or a different preparation is a different question.
The form that was studied
Oral
✎ Source-linked record
Where this came from
A person wrote this into the record with the study named beside it. No reviewer has signed it off.
The form used in the studies cited on this page.
No source is stored against this line.
What is sold
Not recorded.
∅ Nothing recorded
Where this came from
RNAWiki holds nothing here and says so rather than guessing.
Nothing further is recorded about which forms are sold.
No source is stored against this line.
What is recorded as being sold
31 products list this as an active ingredient in the United States drug directory. 31 of them contain it and nothing else.
FDA National Drug Code directory · 17337-0031 · read 2026-08-29
They are sold as capsule, injection, powder, lyophilized, for solution and powder, taken intravenous and oral.
FDA National Drug Code directory · 17337-0031 · read 2026-08-29
The regulator's established pharmacologic class for it is rifamycin antibacterial [epc] and rifamycins [cs].
FDA National Drug Code directory · 17337-0031 · read 2026-08-29
14 published labels name it as an active ingredient. 14 of them describe this substance alone, which is where its own label text on this page comes from.
US prescribing information · cb59a48c-f66b-4ea0-809c-de0e4be2f8c2 · read 2026-08-29
Those labels are classed as human prescription drug.
US prescribing information · cb59a48c-f66b-4ea0-809c-de0e4be2f8c2 · read 2026-08-29
Rifampin is intravenous at HOW SUPPLIED Rifampin for Injection, USP is available in sterile glass vials containing 600 mg rifampin (NDC 0143-9230-01)., recorded as fda label in effect 2022-01-28 in the United States.
US prescribing information · cb59a48c-f66b-4ea0-809c-de0e4be2f8c2 · read 2026-08-30
Recorded price in US: 0.68021–0.80348 USD per one unit as the pricing file counts it — a tablet, capsule, patch or single item, across 12 priced products whose strengths and pack forms differ, as of 2026-08-26, paid by retail pharmacies buying the product, as surveyed by the Centers for Medicare & Medicaid Services. It is not a list price, an insurance price, or what anyone pays at a counter..
Recorded source · 2026-08-26 · read 2026-08-28
Evidence carries across two names for one substance. It does not carry across a salt, a mirror form or a mixture.
What it would be like to take◇Read from sources, not yet reviewed
What you could measure
This one is decided with a clinician, so this section holds questions to ask rather than a plan to run.
Self-experiment planning is not offered for a prescription or clinician-supervised medicine. The questions below are for a clinician or pharmacist.
Questions worth asking
Which of the trials of Rifampicin studied people like me?
What was measured, and for how long?
Was the result a laboratory value or a health outcome?
What would we watch for, and when would we stop?
Tracking can show whether something changed for you. It cannot show what caused it.
RNAWiki records evidence. It does not say whether this substance is right for you.
What is missing or unclear◇Read from sources, not yet reviewed
What nobody knows yet
Open questions, each with why it is open and what would close it.
Missing populations
Which groups were under-represented in the studies has not been recorded.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Missing long-term data
No completed tested study window is recorded.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
No reviewed conclusion
RNAWiki has not yet published a reviewed conclusion for this use.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Missing interaction studies
No interaction was found in the registers checked. Not finding one is not the same as showing there is none.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Formulation uncertainty
Several salts, forms or products of Rifampicin are recorded. Results from one form may not transfer to another.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Mechanism not reviewed
No reviewed mechanism story exists for this substance.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
What happened in people◇Read from sources, not yet reviewed
Check any of this yourself
Every line above traced back to the study it came from. This is the technical layer, and the vocabulary changes here.
How many documents were read
14 documents were read for this substance.
RNAWiki source record
Where else this substance is registered
FDA substance identifier (UNII)
VJT6J7R4TR
RxNorm concept
312821
Checks this page had to pass
✓ Passed
Identity resolved
no open identity hold
✓ Passed
No unresolved merge across substance families
no quarantine open
✓ Passed
Every public sentence names a source
The opening statement carries the origin: Quoted from a stored source.
✗ Not passed
Trial roles classified for highlighted evidence
No registered study is classified as testing this substance.
✓ Passed
No internal keys in reader text
enforced by the copy-contract test over the rendered page
✓ Passed
Safety mode resolved
Suppression classes recorded: S4.
✓ Passed
Canonical metadata present
slug and display name present
What is missing or unclear◇Read from sources, not yet reviewed
How this medicine reached us
Kept near the foot of the page. A historical event moves up only when it changes something about this substance today.
What the approval register records
18 approved applications cover products containing this substance. The earliest was NDA050429, approved 19710521 to OXFORD PHARMS.
This order is fixed in code and does not count clicks or time on the page.
What is not here
9 questions this page could not answer
These sections were prepared and left out because there was nothing to put in them. They are listed rather than hidden, so the gaps in this record are visible.
What was measured, goal by goal — found nothing in the sources checked.
How close this is to real life — found nothing in the sources checked.
The path through the body — found nothing in the sources checked.
Felt, measured, or meaningful — found nothing in the sources checked.
How long anything takes — found nothing in the sources checked.
What it may clash with — found nothing in the sources checked.
Other ways to the same goal — found nothing in the sources checked.
Claims that go past the evidence — found nothing in the sources checked.
What changed on this page — found nothing in the sources checked.
The record as stored
The full record, for auditing
Everything above is built from what is below. This layer keeps the technical vocabulary, record identifiers and every stored row, so a reader who wants to check the page can.
Recorded evidence blocks (11)
Q2
On the Rifampicin label: indicated for what?
"In the treatment of both tuberculosis and the meningococcal carrier state, the small number of resistant cells present within large populations of susceptible cells can rapidly become the predominant type. Bacteriologic cultures should be obtained before the start of therapy to confirm the susceptibility of the…": indications and usage on Rifampicin's label. DailyMed label · cb59a48c-f66b-4ea0-809c-de0e4be2f8c2 · 2022-01-28
Q3
305 registered trials of Rifampicin — at which phases?
Registered studies posting no result
239 of 305
305 registered studies of Rifampicin: 183 phase1, 43 phase2, 34 phase3, 22 phase4, 21 na, 4 early phase1, 4 na or unstated. CLINICALTRIALS_SNAPSHOT · 2026-09-01
"DSMB recommended stopping the study after an interim analysis of the primary endpoint revealed that futility criteria were met."; 18 of 305 registered studies
Show the evidence
Trial
NCT01287221
terminated; "DSMB recommended stopping the study after an interim analysis of the primary endpoint revealed that futility criteria were met."
NCT01349192
terminated; "Interim review showed a statistically significant treatment effect and the DMC recommended that the study be stopped with ongoing follow-up of enrolled subjects"
NCT01441206
terminated; "Study to be redesigned."
NCT01601626
terminated; "The study was stopped early due to feasibility concerns."
NCT01756924
terminated; "This study has been terminated; alternative study designs are being considered. Fusidic acid remains available under an Expanded Access Protocol."
NCT01969682
withdrawn; "This study will be conducted in healthy volunteer subjects."
12 further recorded trials
NCT02099240
terminated; "Not enough patient enrollment and lack of staffing"
NCT02387242
suspended; "New relevant data published"
NCT02547116
withdrawn; "Administrative delay"
NCT02875223
terminated; "Business objectives have changed"
NCT03173053
terminated; "Results interim-analysis"
NCT04150367
terminated; "According to Sponsor decision."
NCT04301310
withdrawn; "Business objectives have changed"
NCT04311502
terminated; "Accrual was permanently closed due to futility in the experimental arm on June 22, 2023. Follow-up in the experimental arm was extended to 117 weeks."
NCT04312282
terminated; "The Sponsor has discontinued the development of tesetaxel"
NCT04558216
withdrawn; "Withdrawn due to unavailability of rifampin for clinical trial use"
NCT04694586
suspended; "Suspended 15th of Nov 2023 due to conditions affecting recruitment process."
NCT04959266
terminated; "The study terminated because the clinical development programme for Adavosertib has been discontinued"
recorded 2026-09-01 · last checked 2026-09-04
Q5
Human studies of Rifampicin used rifapentine 10 mg/kg — over how long?
studies of Rifampicin used the recorded amount. ClinicalTrials.gov · 2026-09-01
19 recorded entries; human; infusion; also "rifapentine 10 mg/kg", "rifapentine 15 mg/kg", "rifapentine 20 mg/kg"
Show the evidence
human
NCT00694629
rifapentine 10 mg/kg
NCT00694629
rifapentine 15 mg/kg
NCT00694629
rifapentine 20 mg/kg
NCT01845298
Rifampicin 600 mg
NCT02085967
rifampin 600 mg
NCT02174250
Rifampin 300mg BID + istradefylline 40mg Day 8 only
13 more recorded rows
humanNCT02706535
Rifampicin 300 mg
humanNCT02807116
PAC400 mg and rifampin 600mg
humanNCT03278483
Rifampin 600 mg Oral Tablet
humanNCT03326050
Rifampicin 150Mg Capsule
humanNCT03982277
Rifampin 300 Mg Oral Capsule
humanNCT04029584
Rifadin 300Mg Capsule
humanNCT04150367
infusion; Rifampin, Lyophilisate for solution for infusion 600 mg.
humanNCT04150367
Rifampicin 150 mg Capsules
humanNCT04463680
Rifampin 600 MG
humanNCT04510649
Rifampin 600 mg
humanNCT04830462
Rifampicin 300 Mg Oral Capsule
humanNCT05917340
High dose rifampicin (25mg/kg)
humanNCT05991401
Rifampicin 600mg
recorded 2026-09-01 · last checked 2026-09-04
Q6
Rifampicin's half-life is 1.04 to 3.81 hours — which schedules were studied?
1.04 to 3.81 hours, the half-life Rifampicin's label states: "The individual serum half-life of rifampin changed from 1.04 to 3.81 hours early in therapy to 1.17 to 3.19 hours 5 to 14 days after therapy was initiated." DailyMed label · cb59a48c-f66b-4ea0-809c-de0e4be2f8c2 · 2022-01-28
tmax 1 to 4 days.
Show the evidence
half lifepharmacokinetics
1.04 to 3.81 hours; The individual serum half-life of rifampin changed from 1.04 to 3.81 hours early in therapy to 1.17 to 3.19 hours 5 to 14 days after therapy was initiated.
tmaxpharmacokinetics
1 to 4 days; In pediatric patients 0.25 to 12.8 years old (n=12), the mean peak serum concentration of rifampin at the end of a 30-minute infusion of approximately 300 mg/m 2 was 25.9 ± 1.3 mcg/mL; individual peak concentrations 1 to 4 days after initiation of therapy ranged from 11.7 to 41.5 mcg/mL; individual peak concentrations 5 to 14 days after initiation of therapy were 13.6 to 37.4 mcg/mL.
recorded 2022-01-28 · last checked 2026-09-04
Q7
Which running trial of Rifampicin could settle lifespan?
NCT04951986 measures All-cause mortality, reading out 2026-03.
2 open trials; n 732; "Testing New Strategies for Patients Hospitalised With HIV-associated Disseminated Tuberculosis"
Show the evidence
Trial
NCT04951986
"Testing New Strategies for Patients Hospitalised With HIV-associated Disseminated Tuberculosis"; n 732; "All-cause mortality"; 2026-03
NCT05917340
"Intensified Short Course Regimen for TBM in Adults"; n 372; "Mortality rate"; 2027-09
Q8
Which 163 trials of Rifampicin posted no result?
Posted no result
163 of 163 completed trials
Registrations
NCT00000641, NCT00001033, NCT00000636, NCT00004689, NCT00000796 and NCT00000638, and 157 more
Completion dates
oldest 1994-12; newest 2024-08-19
Show the evidence
Trial
NCT00000641
1994-12
NCT00001033
1997-07
NCT00000636
1997-10
NCT00004689
1998-09
NCT00000796
1998-10
NCT00000638
1999-09
14 further recorded trials
NCT00127504
2004-05
NCT00317330
2005-06
NCT00384280
2006-11
NCT00405080
2007-01-05
NCT00096850
2007-12
NCT00741169
2008-12
NCT00776516
2008-12
NCT00057122
2009-06
NCT00568711
2009-12
NCT01018368
2010-03
NCT01406002
2010-03
NCT02216331
2010-05
NCT00985270
2010-10
NCT01002079
2010-10
Q9
At the median, Rifampicin's trials enrolled 38 people — anything larger?
Median enrolment
38
Largest enrolment
144000
Registered trials counted
305
Q10
What do 4087 spontaneous reports say about Rifampicin — and not say?
These are reports people sent to a regulator. They do not show the medicine caused the reaction. Nobody counted how many people took the medicine and reported nothing. The same event can be reported more than once, and many reports are incomplete. News coverage, lawsuits and new warnings change how often people report. A count is not a rate and not a risk.
Rifampicin appears in spontaneous reports to regulators. Across the 10 most-reported reaction terms, 4087 reaction mentions were counted: drug reaction with eosinophilia and systemic symptoms 734; pyrexia 639; drug interaction 550; paradoxical drug reaction 414. FAERS via Open Targets · CHEMBL374478 · 2026-06-24
Show the evidence
drug reaction with eosinophilia and systemic symptoms
734
pyrexia
639
drug interaction
550
paradoxical drug reaction
414
acute kidney injury
357
drug-induced liver injury
349
4 more recorded rows
drug resistance
288
thrombocytopenia
286
eosinophilia
245
rash maculo-papular
225
recorded 2026-06-24 · last checked 2026-09-04
Q11
Which 10 reactions does Rifampicin's label not list?
Effect of rifampin on other drugs Induction of Drug Metabolizing Enzymes and Transporters Drug metabolizing enzymes and transporters affected by rifampin include cytochromes P450 (CYP) 1A2, 2B6, 2C8, 2C9, 2C19, and 3A4, UDP-glucuronyltransferases (UGT), sulfotransferases, carboxylesterases, and transporters including P-glycoprotein (P-gp) and multidrug resistance-associated protein 2 (MRP2).
drug_interactions
Most drugs are substrates for one or more of these enzyme or transporter pathways and these pathways may be induced by rifampin simultaneously.
drug_interactions
Decrease AUC by 56% Narcotic Analgesics Oxycodone Decrease AUC by 86% Morphine Decrease exposure Selective 5-HT3 Receptor Antagonists Ondansetron Decrease exposure Statins Metabolized by CYP3A4 Simvastatin Decrease exposure Thiazolidinediones Rosiglitazone Decrease AUC by 66% Tricyclic Antidepressants Nortriptyline i Decrease exposure Other Drugs Enalapril Decrease active metabolite exposure…
ChEMBL 37 — CC BY-SA 3.0 Unported · ChEMBL ATC CC BY-SA · ClinicalTrials.gov — US Government work · Open Targets 26.06 — CC0 · mixed register set; per-register licences in docs/specs/corpus-20k-sources.md · openFDA / DailyMed — US Government work
✗ required summary fields resolved: 4 required field(s) not terminal: Why people use it, Best-supported result, Biggest unanswered question, Human evidence
✓ public claims reviewed: 0 reviewed claim(s); drafts are never rendered
✓ source coverage passed: 6 source rows
✓ no critical contamination: no quarantine open
✓ canonical metadata passed: slug and display name present
✓ no raw internal fields: enforced by the copy-contract test over the rendered page
This is a record of evidence. It is not medical advice, and it does not say this substance suits you. Nothing here says any substance on RNAWiki is appropriate for a child.